Annual Report And Accounts

Overview

The report describes Futura's transition toward commercialization, including UKCA approval and marketing authorizations in the Middle East. It highlights the Cooper and Menarini licensing agreements, manufacturing scale-up and initial production orders. Futura also completed the FM71 Phase 3 study, submitted a US FDA De Novo dossier and reported no serious adverse events in MED3000 subjects.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2022
Period: Ends 31 December 2022
Publication date: 4 April 2023
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services